Nov 2026· Cancers· Vol 18, pp. 3600· 0 citations· 81 references
TL;DR
Renal cell carcinoma is increasingly recognized as a metabolic disease driven by genetic alterations that regulate cellular energetics, and recent advances in targeting these pathways are highlighted, alongside emerging metabolic biomarkers and imaging modalities.
Abstract
Renal cell carcinoma (RCC) is increasingly recognized as a metabolic disease driven by genetic alterations that regulate cellular energetics. In clear cell RCC (ccRCC), loss of the von Hippel-Lindau (VHL) gene stabilizes hypoxia-inducible factors (HIFs), promoting a pseudo-hypoxic state that enhances glycolysis, suppresses mitochondrial oxidation, and remodels lipid metabolism. Here we review how these metabolic reprogramming events, including glutamine dependence and oncometabolite accumulation in rarer subtypes, reshape the tumor microenvironment and contribute to immune evasion. We highlight recent advances in targeting these pathways, notably the clinical success of the HIF-2α inhibitor belzutifan, alongside emerging metabolic biomarkers and imaging modalities. These insights underscore the potential of metabolism-based strategies to improve RCC diagnosis and therapy while emphasizing the complex interplay between tumor metabolism and immune regulation.
Colorectal cancer (CRC) continues to pose a significant global health concern, largely driven by metabolic reprogramming mechanisms that facilitate tumor progression and enable immune evasion within the tumor microenvironment (TME). This review highlights the pivotal functions of dysregulated metabolic pathways, such...
Alireza Najafi, Ali Rahimi, Zeinab Baghernejadian et al.· Cancer Cell International· 0 citations
Renal cell carcinoma (RCC), particularly clear cell RCC (ccRCC), exhibits extensive metabolic, signaling, and microenvironmental remodeling associated with dysregulated VHL-HIF signaling. HIF activation in RCC may arise from VHL loss under normoxic conditions and from genuine tumor hypoxia due to inadequate oxygen avai...
Malleshwari Mahalinga, A. Rai, T. Prasad· Journal of Proteome Research· 0 citations
Renal cell carcinoma (RCC), particularly its clear-cell subtype (ccRCC), is characterized by metabolic reprogramming and a complex tumor microenvironment that influence responses to immune checkpoint inhibitors (ICIs). Despite clinical advances, therapeutic resistance remains a major hurdle. Here we review the molecula...
M. Milella, F. Lasorsa, M. Rutigliano et al.· Cells· 0 citations
Colorectal cancer (CRC) is one of the most prevalent malignancies of the gastrointestinal tract worldwide. Notably, most patients with microsatellite-stable (MSS) tumors show primary resistance to immune checkpoint inhibitors (ICIs), creating an unmet clinical need. The mechanisms underlying immune evasion and strategi...
Dai-Xun Ding, Jing-Yi Hu, Yi-Tong Wang et al.· International Journal of Mol...· 0 citations
Hepatocellular carcinoma (HCC) arises in chronically injured, often fibrotic or cirrhotic liver, where metabolism, immunity, vascular and stromal organization, disease etiology, tumor state, and hepatic reserve are tightly interconnected. Although immune checkpoint inhibitor (ICI)-based therapies have expanded treatmen...
Chun-Yan Dai, Shengying Lou, Hua-Li Luo et al.· Pharmacological Research· 0 citations
Osteosarcoma (OS) remains difficult to cure once it becomes metastatic, recurrent, or resistant to chemotherapy, and immune checkpoint blockade has provided limited clinical benefit. The metabolic-immune tumor microenvironment (TME) is one barrier to effective immunity because malignant, stromal, and immune cells compe...
Jia-Wei Yin, Shuai Lu, Yi-Kai Liu et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.